| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 19 | 2024 | 1057 | 2.860 |
Why?
|
| Medical Oncology | 6 | 2024 | 375 | 2.780 |
Why?
|
| Artificial Intelligence | 7 | 2024 | 311 | 1.980 |
Why?
|
| Neoplasms | 14 | 2024 | 2996 | 1.780 |
Why?
|
| Neoplastic Stem Cells | 10 | 2021 | 160 | 1.440 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2024 | 132 | 1.430 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2022 | 1093 | 1.390 |
Why?
|
| Salivary Gland Neoplasms | 6 | 2021 | 67 | 1.250 |
Why?
|
| Papillomavirus Infections | 5 | 2024 | 260 | 1.170 |
Why?
|
| Carcinoma, Adenoid Cystic | 5 | 2018 | 29 | 1.100 |
Why?
|
| Humans | 88 | 2024 | 88286 | 0.910 |
Why?
|
| Hematology | 1 | 2023 | 30 | 0.900 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2022 | 6 | 0.880 |
Why?
|
| Biomarkers, Tumor | 6 | 2022 | 1519 | 0.880 |
Why?
|
| Ovarian Neoplasms | 4 | 2024 | 757 | 0.860 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1104 | 0.850 |
Why?
|
| Lenses | 1 | 2022 | 5 | 0.850 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 611 | 0.840 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2023 | 148 | 0.820 |
Why?
|
| Medicine | 1 | 2022 | 90 | 0.810 |
Why?
|
| Carcinoma | 2 | 2022 | 441 | 0.800 |
Why?
|
| Lens, Crystalline | 1 | 2022 | 69 | 0.790 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 2529 | 0.790 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 62 | 0.760 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 14 | 0.760 |
Why?
|
| Specimen Handling | 1 | 2021 | 101 | 0.750 |
Why?
|
| Academies and Institutes | 1 | 2020 | 31 | 0.750 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 16 | 0.750 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 35 | 0.740 |
Why?
|
| Microsatellite Instability | 4 | 2021 | 49 | 0.730 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2024 | 1226 | 0.730 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 1253 | 0.710 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 8 | 0.710 |
Why?
|
| ras Proteins | 1 | 2020 | 130 | 0.700 |
Why?
|
| Mouth Neoplasms | 4 | 2023 | 195 | 0.700 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 146 | 0.690 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 294 | 0.690 |
Why?
|
| Cyclin D1 | 1 | 2019 | 84 | 0.690 |
Why?
|
| Machine Learning | 7 | 2023 | 241 | 0.680 |
Why?
|
| Adenocarcinoma | 3 | 2023 | 1183 | 0.670 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 2325 | 0.660 |
Why?
|
| Leadership | 1 | 2020 | 136 | 0.660 |
Why?
|
| Cell Proliferation | 9 | 2024 | 1638 | 0.650 |
Why?
|
| Breast Neoplasms | 7 | 2023 | 2972 | 0.620 |
Why?
|
| Neoplasm Staging | 7 | 2022 | 1974 | 0.610 |
Why?
|
| Carcinoma, Mucoepidermoid | 4 | 2019 | 17 | 0.600 |
Why?
|
| Cell Line, Tumor | 19 | 2024 | 2528 | 0.600 |
Why?
|
| Transcriptome | 2 | 2021 | 619 | 0.570 |
Why?
|
| Mutation | 7 | 2024 | 4090 | 0.560 |
Why?
|
| Patient Selection | 1 | 2020 | 686 | 0.560 |
Why?
|
| Precision Medicine | 1 | 2021 | 407 | 0.560 |
Why?
|
| Papillomaviridae | 3 | 2022 | 155 | 0.550 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 417 | 0.540 |
Why?
|
| Antineoplastic Agents | 9 | 2023 | 2402 | 0.520 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2021 | 469 | 0.460 |
Why?
|
| Receptor, ErbB-2 | 5 | 2023 | 236 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2024 | 1349 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2018 | 32 | 0.440 |
Why?
|
| Female | 37 | 2024 | 45560 | 0.420 |
Why?
|
| Interleukin-6 | 3 | 2020 | 260 | 0.420 |
Why?
|
| Mice | 24 | 2024 | 11682 | 0.400 |
Why?
|
| Prognosis | 8 | 2023 | 3740 | 0.390 |
Why?
|
| Immunotherapy | 9 | 2023 | 655 | 0.390 |
Why?
|
| Tumor Burden | 4 | 2022 | 303 | 0.380 |
Why?
|
| Stomach Neoplasms | 3 | 2023 | 268 | 0.380 |
Why?
|
| Colorectal Neoplasms | 4 | 2024 | 965 | 0.370 |
Why?
|
| Neoplasm Metastasis | 4 | 2024 | 1095 | 0.370 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 447 | 0.370 |
Why?
|
| Middle Aged | 22 | 2024 | 25571 | 0.330 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 366 | 0.320 |
Why?
|
| Models, Biological | 3 | 2022 | 1764 | 0.310 |
Why?
|
| Estrogen Receptor alpha | 2 | 2019 | 147 | 0.310 |
Why?
|
| Animals | 27 | 2024 | 27127 | 0.310 |
Why?
|
| Algorithms | 5 | 2024 | 1857 | 0.310 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 300 | 0.300 |
Why?
|
| Mice, SCID | 6 | 2018 | 261 | 0.300 |
Why?
|
| Cisplatin | 6 | 2022 | 615 | 0.300 |
Why?
|
| Paclitaxel | 5 | 2024 | 477 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2017 | 14 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2017 | 29 | 0.280 |
Why?
|
| B7-H1 Antigen | 4 | 2023 | 267 | 0.280 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2018 | 408 | 0.280 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1423 | 0.250 |
Why?
|
| Signal Transduction | 7 | 2024 | 3358 | 0.250 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 539 | 0.250 |
Why?
|
| Male | 21 | 2024 | 41840 | 0.240 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2021 | 17 | 0.240 |
Why?
|
| Quantum Theory | 1 | 2024 | 30 | 0.240 |
Why?
|
| Membrane Glycoproteins | 2 | 2016 | 431 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 2 | 2024 | 357 | 0.240 |
Why?
|
| Computers | 1 | 2024 | 112 | 0.240 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 857 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 954 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 73 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 340 | 0.230 |
Why?
|
| Quinolones | 1 | 2024 | 60 | 0.230 |
Why?
|
| Xerostomia | 1 | 2023 | 10 | 0.230 |
Why?
|
| DNA, Mitochondrial | 2 | 2024 | 187 | 0.220 |
Why?
|
| Mouth Diseases | 1 | 2023 | 16 | 0.220 |
Why?
|
| Oral Medicine | 1 | 2023 | 4 | 0.220 |
Why?
|
| Drug Design | 1 | 2023 | 124 | 0.220 |
Why?
|
| Cohort Studies | 5 | 2021 | 2827 | 0.210 |
Why?
|
| Piperazines | 3 | 2019 | 280 | 0.210 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.210 |
Why?
|
| Pyridines | 3 | 2019 | 316 | 0.210 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2023 | 317 | 0.210 |
Why?
|
| Uncertainty | 1 | 2022 | 73 | 0.210 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2021 | 4 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 126 | 0.200 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 33 | 0.200 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 199 | 0.200 |
Why?
|
| Cloud Computing | 1 | 2021 | 11 | 0.200 |
Why?
|
| Aged | 12 | 2024 | 18834 | 0.200 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 71 | 0.200 |
Why?
|
| Data Accuracy | 1 | 2021 | 31 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2022 | 119 | 0.190 |
Why?
|
| DNA, Viral | 1 | 2022 | 265 | 0.190 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 55 | 0.190 |
Why?
|
| Neck Dissection | 1 | 2021 | 65 | 0.190 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 41 | 0.190 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.190 |
Why?
|
| Endogenous Retroviruses | 1 | 2020 | 10 | 0.190 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 167 | 0.190 |
Why?
|
| Neoplasms, Experimental | 2 | 2020 | 269 | 0.190 |
Why?
|
| Acetophenones | 1 | 2020 | 27 | 0.190 |
Why?
|
| Mitochondria | 1 | 2024 | 547 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 82 | 0.180 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 25 | 0.180 |
Why?
|
| Recombinational DNA Repair | 1 | 2020 | 9 | 0.180 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 19 | 0.180 |
Why?
|
| 4-1BB Ligand | 1 | 2020 | 3 | 0.180 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2020 | 17 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 602 | 0.180 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 96 | 0.180 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 89 | 0.180 |
Why?
|
| User-Computer Interface | 1 | 2021 | 187 | 0.180 |
Why?
|
| Actomyosin | 1 | 2020 | 46 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2024 | 681 | 0.180 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 392 | 0.180 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 26 | 0.180 |
Why?
|
| Software | 1 | 2024 | 661 | 0.170 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 531 | 0.170 |
Why?
|
| Naphthalenes | 1 | 2019 | 45 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 185 | 0.170 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 476 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 477 | 0.170 |
Why?
|
| Mitosis | 2 | 2017 | 152 | 0.170 |
Why?
|
| Quinolines | 1 | 2019 | 91 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2022 | 8125 | 0.170 |
Why?
|
| Cytoskeleton | 1 | 2020 | 194 | 0.170 |
Why?
|
| Retrospective Studies | 6 | 2023 | 8836 | 0.170 |
Why?
|
| Point Mutation | 1 | 2019 | 247 | 0.160 |
Why?
|
| Olfactory Mucosa | 1 | 2018 | 33 | 0.160 |
Why?
|
| Cell Adhesion | 2 | 2020 | 425 | 0.160 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 29 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 53 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 157 | 0.160 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 172 | 0.160 |
Why?
|
| Pyrrolidines | 1 | 2018 | 59 | 0.160 |
Why?
|
| Indoles | 1 | 2020 | 308 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 110 | 0.160 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 740 | 0.150 |
Why?
|
| Computational Biology | 1 | 2021 | 536 | 0.150 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 131 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 661 | 0.150 |
Why?
|
| Prospective Studies | 3 | 2023 | 4257 | 0.150 |
Why?
|
| Carboplatin | 3 | 2024 | 302 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 166 | 0.150 |
Why?
|
| Students, Medical | 1 | 2023 | 417 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 408 | 0.150 |
Why?
|
| Capecitabine | 1 | 2017 | 98 | 0.150 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2016 | 15 | 0.140 |
Why?
|
| Logistic Models | 1 | 2020 | 1202 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 500 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2020 | 546 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2018 | 469 | 0.140 |
Why?
|
| Gossypol | 1 | 2016 | 6 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 386 | 0.140 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 49 | 0.140 |
Why?
|
| Trans-Activators | 1 | 2019 | 443 | 0.140 |
Why?
|
| Time Factors | 4 | 2020 | 5299 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2017 | 235 | 0.140 |
Why?
|
| Retinal Dehydrogenase | 1 | 2015 | 7 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2016 | 107 | 0.130 |
Why?
|
| Taxoids | 1 | 2016 | 130 | 0.130 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 38 | 0.130 |
Why?
|
| Biostatistics | 1 | 2015 | 20 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 2331 | 0.130 |
Why?
|
| Cell Separation | 1 | 2016 | 198 | 0.130 |
Why?
|
| Risk Factors | 3 | 2021 | 5430 | 0.130 |
Why?
|
| Aniline Compounds | 1 | 2015 | 58 | 0.130 |
Why?
|
| Cell Division | 1 | 2016 | 696 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2015 | 235 | 0.120 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 306 | 0.120 |
Why?
|
| Isoenzymes | 1 | 2015 | 272 | 0.120 |
Why?
|
| Adult | 11 | 2024 | 26230 | 0.120 |
Why?
|
| Microbiota | 1 | 2020 | 394 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 773 | 0.120 |
Why?
|
| United States | 3 | 2022 | 6857 | 0.120 |
Why?
|
| Models, Theoretical | 3 | 2023 | 489 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2021 | 749 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1057 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 723 | 0.120 |
Why?
|
| Drug Synergism | 3 | 2020 | 305 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2021 | 2281 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 447 | 0.110 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 396 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2024 | 267 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2015 | 318 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 1212 | 0.100 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2011 | 16 | 0.100 |
Why?
|
| Mice, Nude | 3 | 2020 | 813 | 0.100 |
Why?
|
| BRCA2 Protein | 2 | 2023 | 159 | 0.100 |
Why?
|
| BRCA1 Protein | 2 | 2023 | 201 | 0.090 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 125 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 1710 | 0.090 |
Why?
|
| Apoptosis | 4 | 2018 | 1713 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 63 | 0.090 |
Why?
|
| Methylmercury Compounds | 1 | 2009 | 3 | 0.080 |
Why?
|
| Milk, Human | 1 | 2009 | 44 | 0.080 |
Why?
|
| Hair | 1 | 2009 | 56 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 498 | 0.080 |
Why?
|
| Intelligence | 1 | 2009 | 71 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 372 | 0.080 |
Why?
|
| Phenotype | 3 | 2021 | 2430 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6687 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 1685 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 902 | 0.070 |
Why?
|
| Biomarkers | 2 | 2023 | 1753 | 0.070 |
Why?
|
| Cytokines | 2 | 2021 | 801 | 0.070 |
Why?
|
| Endothelial Cells | 2 | 2020 | 453 | 0.070 |
Why?
|
| Cell Survival | 2 | 2018 | 979 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 861 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1943 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2018 | 508 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1703 | 0.060 |
Why?
|
| Quality of Life | 2 | 2023 | 1646 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2024 | 23 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2742 | 0.060 |
Why?
|
| Perforin | 1 | 2023 | 55 | 0.060 |
Why?
|
| Phthalazines | 1 | 2023 | 43 | 0.060 |
Why?
|
| European Union | 1 | 2023 | 8 | 0.060 |
Why?
|
| Pathology, Oral | 1 | 2023 | 5 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 164 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 38 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Adolescent | 3 | 2022 | 9125 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2023 | 477 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 292 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2023 | 107 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 141 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 130 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 134 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2023 | 133 | 0.050 |
Why?
|
| Switzerland | 1 | 2021 | 17 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 31 | 0.050 |
Why?
|
| Histological Techniques | 1 | 2021 | 35 | 0.050 |
Why?
|
| Germany | 1 | 2021 | 72 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 272 | 0.050 |
Why?
|
| Italy | 1 | 2021 | 107 | 0.050 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 19 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 276 | 0.050 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2021 | 23 | 0.050 |
Why?
|
| United Kingdom | 1 | 2021 | 161 | 0.050 |
Why?
|
| Japan | 1 | 2021 | 303 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 149 | 0.050 |
Why?
|
| Shoulder | 1 | 2021 | 42 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 80 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2020 | 6 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2020 | 10 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2020 | 2 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 559 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 31 | 0.050 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 20 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2020 | 33 | 0.050 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2020 | 23 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2020 | 30 | 0.050 |
Why?
|
| Oncogenic Viruses | 1 | 2020 | 4 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2020 | 154 | 0.050 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 16 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2020 | 91 | 0.040 |
Why?
|
| Environmental Microbiology | 1 | 2020 | 22 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 97 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 171 | 0.040 |
Why?
|
| Learning | 1 | 2023 | 283 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 19 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 83 | 0.040 |
Why?
|
| Helicobacter Infections | 1 | 2020 | 36 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 62 | 0.040 |
Why?
|
| Gastritis | 1 | 2020 | 33 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2020 | 81 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 574 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1186 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 769 | 0.040 |
Why?
|
| Rad51 Recombinase | 1 | 2020 | 80 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 79 | 0.040 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 47 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2019 | 133 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 234 | 0.040 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2018 | 7 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2020 | 152 | 0.040 |
Why?
|
| Symbiosis | 1 | 2020 | 122 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2018 | 18 | 0.040 |
Why?
|
| Probiotics | 1 | 2020 | 85 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 76 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 121 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2018 | 67 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 294 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 100 | 0.040 |
Why?
|
| Young Adult | 2 | 2022 | 6171 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 354 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 263 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2018 | 91 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 206 | 0.040 |
Why?
|
| Cadherins | 1 | 2018 | 160 | 0.040 |
Why?
|
| Estrogens | 1 | 2018 | 201 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 773 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 234 | 0.040 |
Why?
|
| Time-Lapse Imaging | 1 | 2017 | 20 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 1083 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 283 | 0.040 |
Why?
|
| Actins | 1 | 2020 | 456 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 684 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2020 | 496 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1568 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2016 | 10 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 215 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1141 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2018 | 463 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 760 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2016 | 19 | 0.040 |
Why?
|
| Breast | 1 | 2018 | 290 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 119 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 783 | 0.040 |
Why?
|
| Spiro Compounds | 1 | 2016 | 25 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1542 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 127 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2017 | 65 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2016 | 65 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1241 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1846 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 122 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 121 | 0.030 |
Why?
|
| G1 Phase | 1 | 2016 | 65 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 846 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2016 | 166 | 0.030 |
Why?
|
| Bacteria | 1 | 2020 | 466 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 237 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 583 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 102 | 0.030 |
Why?
|
| Neprilysin | 1 | 2015 | 41 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1213 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 141 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2873 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1837 | 0.030 |
Why?
|
| Pyrroles | 1 | 2016 | 185 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 106 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 435 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 85 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 161 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 1112 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 329 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 658 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1481 | 0.030 |
Why?
|
| Publishing | 1 | 2015 | 91 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 371 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1787 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 427 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1238 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3191 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 691 | 0.030 |
Why?
|
| Child | 2 | 2019 | 7074 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 168 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 486 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 317 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 1095 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1881 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 429 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 860 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1587 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 1126 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1511 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1659 | 0.030 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2011 | 9 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1398 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2319 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 377 | 0.020 |
Why?
|
| Seychelles | 1 | 2009 | 2 | 0.020 |
Why?
|
| Mercury | 1 | 2009 | 8 | 0.020 |
Why?
|
| Seafood | 1 | 2009 | 10 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2009 | 58 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 1762 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2015 | 1036 | 0.020 |
Why?
|
| Aging | 1 | 2009 | 708 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 3109 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 3667 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 2257 | 0.010 |
Why?
|